Added value of 18-F-FDG-PET/CT in patients with pancreatic cancer: Initial observation  by Shaban, Ekhlas Abdelmonem Ibrahem Nasr
The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1275–1282Contents lists available at ScienceDirect
The Egyptian Journal of Radiology and Nuclear Medicine
journal homepage: www.sciencedirect .com/ locate /e j rnmOriginal ArticleAdded value of 18-F-FDG-PET/CT in patients with pancreatic
cancer: Initial observationhttp://dx.doi.org/10.1016/j.ejrnm.2016.07.007
0378-603X/ 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
E-mail address: ekhlas_radiology@med.tanta.edu.eg
Peer review under responsibility of The Egyptian Society of Radiology and
Nuclear Medicine.Ekhlas Abdelmonem Ibrahem Nasr Shaban
Faculty of Medicine, Tanta University, Tanta, Egypta r t i c l e i n f o a b s t r a c tArticle history:
Received 21 May 2016
Accepted 13 July 2016
Available online 21 August 2016
Keywords:
CT
18-F-FDG PET/CT
Pancreatic cancerPurpose: The goal of the study was to highlight the added value of 18-F-FDG PET/CT over
isolated CT to depict pancreatic tumors, distant metastases, monitor response to treatment
and its usefulness in distinguishing fibrosis from residual/recurrence, thus direct biopsy to
sites more likely to yield representative tumor tissue.
Patients and methods: This study included 20 patients for which 18-F-PET/CT scans were
performed. A case based analysis was performed in detailed manner for lesions on CT
and fused images of 18-F-PET/CT. Statistical analysis including specificity, Sensitivity, neg-
ative predictive value (NPV) and positive predictive value (PPV) of each of these modalities
was performed. A final diagnosis of metastasis was confirmed by further clinical and radi-
ological workup.
Results: PET/CT has 100% sensitivity, 88.9% specificity, 91.7% PPV, 100% NPV and 95% accu-
racy compared to 77.8% sensitivity and 54.5% specificity, 58.3% PPV, 75% NPV and 65% accu-
racy for CT in diagnosis and monitoring treatment response.
Conclusion: Combined 18-F FDG PET/CT significantly improves the sensitivity and speci-
ficity of isolated CT for depicting pancreatic tumors, distant metastases, monitor response
to treatment distinguishing fibrosis from residual/recurrence.
 2016 The Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by
Elsevier. This is an open access article under the CC BY-NC-ND license (http://creativecom-
mons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pancreatic carcinoma remains a devastating disease.
Pancreatic cancer is the twelfth most common cancer in
the world; it is the seventh most common cause of death
from cancer. Treatment of this disease remains a major
challenge [1,2].
The long-term outcome of pancreatic cancer is extre-
mely poor, the overall median survival from diagnosis
being 3–6 months without treatment, which increases to
around 23 months with resectional surgery and adjuvanttreatment. Pancreatic cancer is characterized by resistance
to all cancer treatment modalities and early metastasis.
Surgical resection remains the mainstay of treatment for
pancreatic cancer. Curative surgery is rare. Although it
improves the otherwise poor prognosis, it is essentially
palliative in most cases. Adjuvant treatment is recom-
mended for those who undergo resection with curative
intent [3].
Abdominal multidetector computerized tomography
(CT) is the mainstay of diagnostic imaging in patients with
pancreatic cancer. Although it provides excellent anatomic
detail, it may not depict small tumors. Abdominal CT is
conducted every 3–6 months for postoperative monitoring.
It is sometimes difficult to detect local or peritoneal recur-
rences because of postoperative changes in the anatomical
positions of organs [4] (see Figs. 1 and 2).
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Fig. 1. 67 years old male patient, with pancreatic duct adenocarcinoma grade II at pancreatic head, after Whipple operation and chemotherapy. (a) Non
contrast axial CT image shows an ill defined hypodense mass (arrow head) measuring 3.5  3 cm is seen at the operative bed anterior to abdominal aorta at
the level of celiac artery with non visualized pancreatic head and uncinate process. (b) Axial PET and (c) axial PET/CT images show focal area of increased
18-F-FDG uptake (SUVmax 6.7) consistent with that depicted lesion at operative bed (arrow head) denoting residual viable tumor.
Fig. 2. 63 years old male patient with dysplastic pancreatic ductal cell type grade II at pancreatic body invading celiac trunk, no liver or peritoneal deposits,
received 2 cycles of chemotherapy followed by a Nano-Knife ablation. (a) Non contrast axial CT image shows large ill defined hypodense mass at the
operative bed. (b) Axial PET and (c) axial PET/CT images show target-like metabolic activity at operative bed with peripherally located metabolically-active
foci consistent with viable tumor and central photopenic area corresponding to central necrosis. This is denoting a partial therapeutic response.
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imaging modality that has shown promise in tumor depic-
tion, but it is unable to provide detailed high spatial reso-
lution images [5–7].
Fused PET/CT is a recently developed technology that
couples the functional information of PET with the ana-
tomic details of CT [8].
FDG PET imaging is useful for preoperative diagnosis of
pancreatic carcinoma in patients with suspected pancre-
atic cancer in whom CT fails to identify a discrete tumor
mass or in whom FNAs are non diagnostic. FDG PET imag-
ing is useful for M staging and restaging by detecting CT
occult metastatic disease, allowing non curative resection
to be avoided. FDG PET can differentiate post-therapy
changes from recurrence and holds promise for monitoring
neoadjuvant chemoradiation therapy.2. Patients and methods
2.1. Patients
This is a retrospective study carried out in PET/CT unit
at Diagnostic Radiology and Medical Imaging Department
- Tanta University Educational Hospital from July 2015 to
May 2016 for patients with pancreatic cancer after therapy
to differentiate post-treatment fibrosis from residual
viable tumor. A total number of 20 patients were included
in this study, 17 males and 3 females. The mean age of the
patients was 60.25 years and ranged from 47 to 74 years.2.2. Preparation
History was taken from patients regarding when was
the tumor started, types of treatment, whether patients
received chemotherapy or radiotherapy and they were
asked when it was ended, any other co-morbidities (espe-
cially diabetes mellitus so as to control the blood glucose
level), and the patients were also asked to bring last biopsy
histopathological report, creatinine level. Patients were
asked about any newly developed complaint.
All patients were asked to fast for 6 h prior to scan. All
metallic items were removed from the patient, including
pants with zipper, bra, belts, and bracelets, and the
patients were given a gown to wear. An intravenous (IV)
cannula was inserted for administration of 18-F-FDG in
all cases. In this study, real whole body low dose non con-
trast CT was performed. The patients were instructed to
avoid any kind of strenuous activity prior to the examina-
tion and following the injection of the radioisotope to
avoid physiologic muscle uptake of FDG and they were also
asked to void prior to scanning.
Weight and height of patients were measured, and
serum glucose was routinely measured prior to 18-F-FDG
injection. Patients with fasting blood glucose level of less
than 150 mg/dl were permitted to undergo PET/CT.
Diabetic patients (8 patients) were instructed to control
blood glucose level prior to FDG administration by having
half of the morning dose of anti-diabetic treatment with
light breakfast then the blood glucose level was monitored,
when it was within the accepted range and this happenedin 6 cases; we can proceed the study, on the contrary; and
the study was postponed for 2 patients with uncontrolled
serum blood glucose and referred to internal medicine
physician to adjust anti-diabetic treatment for obtaining
optimum blood glucose level at the day of examination .
In order to decrease brown fat, a controlled temperature
(warm) environment was provided for patients before 18-
F-FDG injection and patients were asked to keep high-fat,
low-carbohydrate, protein-permitted diet 24 h before the
examination.
PET/CT was performed at least 6–8 weeks after comple-
tion of treatment to minimize confounding FDG uptake
secondary to post-treatment inflammation.
One and half liters of water was administered to act as
neutral oral contrast agent approximately 1 h before the
examination, and 10 mCi (1 ml/10 kg) 18-F-FDG was
injected manually 45–60 min before examination in the
previously inserted IV canula. This period is referred to as
the uptake phase and is the necessary amount of time for
the 18-FDG to be adequately biodistributed and trans-
ported into the patients’ cells. Patients were asked to rest
in a quiet isolated room, devoid of distractions, and they
were also asked to keep their movements, including talk-
ing, at an absolute minimum. This minimizes physiologic
uptake of 18-F-FDG into skeletal muscles, which can con-
found interpretation of the scan. Patients were ensured
to be comfortable and relaxed.
2.3. Image acquisition and processing
Combined PET/CT scans were performed using hybrid
PET/CT system (Philips, NM Gemini, the Netherlands), con-
sisting of a dedicated PET scanner integrated with a 16
multi-slice CT scanner. This dedicated system permits the
acquisition of co-registered CT and PET images in one
session.
The patients were positioned in a comfortable head fix-
ation with arms up. CT scan was performed from vault to
foot first, by the following parameters: 120 kV, 50 mA,
5-mm slice thickness, and 0.5 mm incremination then
PET study. The whole study took approximately 20–
30 min.
The total length of CT coverage was an integral number
of bed positions scanned during acquisition of PET data.
The study was performed with the patient breathing
quietly.
PET was performed following the CT study without
moving the patient. Approximately 20 bed positions are
planned in the 3-dimensional acquisition mode for scan-
ning the same area with 1–2 min acquisition at each bed
position and there is overlap between bed positions for
PET/CT scan in caudocranial direction.
Helical PET and CT images were first reconstructed.
These were then reformatted into coronal and sagittal
images to facilitate image interpretation. For each of these
sets of PET and CT images, corresponding ‘‘fusion” images
were generated by combining the 2 types of data.
PET image data sets were reconstructed using CT data
for attenuation correction and co-registered images were
displayed using special software and reviewed on the ded-
icated workstation.
Fig. 3. Male patient, 64y with moderately differentiated adenocarcinoma at pancreatic head and hepatic metastasis. The patient received chemotherapy
and referred for assessment of response to therapy. (a) Non contrast axial CT image (pulmonary window) shows pulmonary nodule at the apical segment of
right upper lobe 8 mm, (b) and (c) axial PET and axial PET/CT show that this nodule has abnormal increased FGD uptake than the surrounding background.
(d) Non contrast axial CT image shows multiple hepatic focal lesions, largest at segment III measured 5  3 cm, (e) and (f) axial PET and axial PET/CT images
show that these lesions are metabolically active with increased SUVmax 5.2. (g) Non contrast axial CT image (bone window) does not show any bony
abnormalities (h) and (i) axial PET and axial PET/CT images showmetabolically active bone marrow base osseous lesion at D11 with increased FDG, SUVmax
7. (j) Non contrast axial CT image shows mass at the head of pancreas measured 5  5 cm, (k) and (l) axial PET and axial PET/CT images show that this lesion
is metabolically active with increased SUVmax 7. The overall findings are denoting progressive disease.
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Fig. 4. 58 years old male patient who had neuroendocrine carcinoma at pancreatic neck with peri-neural invasion, peri-pancreatic and para aortic LNs
underwent Whipple surgery, followed by radiotherapy. (a, b) Non contrast CT axial images at the level of the head and body pancreas respectively show
clear operative bed. (c, d) Axial PET images and (e, f) axial PET/CT images at the same levels show no abnormal metabolic activity at the operative bed, and
(g) maximum intensity projection PET image shows absence of detectable metabolically active residual/recurrence lesion or distant metastases.
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All CT examinations were analyzed by experienced
radiologists and all PET/CT examinations were analyzedseparately by a consensus of at least 2 experienced observ-
ing radiologists. The PET images and the volume of CT
scans were evaluated for the presence and extent of 18-
F-FDG-positive disease.
1280 E.A.I.N. Shaban / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1275–1282Interpretation of the PET/CT findings was through visual
assessment and by standardized uptake value (SUV) mea-
surement and comparison of it with the background or
mediastinal blood pool was adequate for interpreting PET
findings as positive or negative.
CT was also useful for detection of coexisting abnormal-
ities that can affect management, such as lung infection.
The diffuse pattern of uptake of reactive bone marrow
hyperplasia after chemotherapy can mimic or mask diffuse
bone marrow involvement; therefore, appropriate history
was critical. A delay of 6–8 weeks after completion of ther-
apy was recommended to permit the physiologic marrow
activity to abate.
Detection and certainty of lesions between the CT eval-
uation and the PET/ CT evaluation were reported.
Follow-up (clinically and by radiological imaging)
served as the reference standard for all patients. True sites
of disease were assigned to sites with concordant positive
findings of clinical evaluation, CT, PET, and PET/CT. Con-
versely, true absence of disease was assigned in concordant
negative findings of clinical evaluation, CT, PET, and PET/
CT. If there is discordance between PET, CT, and PET/CT,
follow-up was used. Lesions were regarded as true positive
if abnormalities either persisted on a follow-up PET or CT
scan with no interval treatment or resolved on a follow-
up scan in patients that had received interval treatment.
Lesions that resolved on follow-up scanning without inter-
val treatment were regarded as false positive. Pathology
(re-biopsy) was recommended for 1 patient.2.5. Statistical analysis
Data were statistically described in terms of
mean ± standard deviation (±SD), median, mode, frequen-
cies (number of cases) and percentages when appropriate.
Sensitivity, specificity, positive and negative predictive val-
ues, and accuracy were calculated to test validity of PET/CT
in assessment of pancreatic cancer. The correlation of P ET/
CT negative residual masses and PET/CT positive residual
masses with standard reference was analyzed using
Chi-square test. P values less than 0.05 were considered
statistically significant. All statistical calculations were
done using computer programs Microsoft Excel 2007
(Microsoft Corporation, NY, USA) and PASW statistics 18
(Predictive Analytics SoftWare; SPSS Inc., PASW statistics
18, Chicago, IL, USA) for Microsoft Windows.3. Results
This study was carried out on 20 patients (17 males and
3 females). Age ranged from 47 to 74 years; the most com-
mon age group between 55 and <60 included 6 patients (5
males and one female). Weight of the studied patients ran-
ged from 50 to 96 kg with a mean of 68.3 and SD 14.35,
while the height of examined patients ranged from 155
to 180 cm with mean of 166.6 and SD 8.21 (Table 1).
Description of the RBS and dose of FDG used for the
patients are summarized in (Table 2).
According to Eastern Cooperative Oncology Group per-
formance status, the most common is grade 1 that depictedin 10 cases, 4 cases had grade 2, other 4 cases had grade 0
and the remaining 2 cases had grade 3 (Table 1).
In this study, Smoking and Diabetes Mellitus were the
most common risk factors where 16 patients were smokers
and 8 were diabetic while 1 patient had history of chronic
pancreatitis (Table 1).
The most common presenting symptom is abdominal
pain followed by jaundice; one case was referred searching
for unknown primary while metastatic hepatic focal lesion
was depicted on ultrasound examination for renal stones.
Adenocarcinoma is the most common histological type
of pancreatic cancer at the studied patient, it was found in
14 cases and the least depicted histological type is intra-
ductal papillary mucinous neoplasm (1 case). Head of pan-
creas had been the commonest site of pancreatic cancer in
the current study followed by pancreatic neck (7 cases and
5 cases) and the least common site was found at tail (2
cases) (Table 1).
As regards treatment received, 2 patients underwent
Nano knife and chemotherapy, 2 patients underwent sur-
gery and chemo-radiotherapy, 2 patients underwent sur-
gery with radiotherapy, 11 patients received
chemotherapy and only 3 patients are newly diagnosed
and not started treatment yet (Table 1).
In this study, PET/CT detects treatment response in 13
cases after chemoradiation therapy, and 4 cases after
surgery-chemo-radiotherapy whereas CT could not differ-
entiate post therapy related changes from residual viable
tumor. Bone marrow based osseous metastases were found
in 2 cases. Hepatic metastases were detected in 6 cases and
pulmonary metastasis in 4 cases. Distant metastasis was
excluded in 12 cases out of examined 20 cases. Three
new cases of pancreatic cancer were included in this study,
2 of them presented with hepatic metastasis (see Figs. 3
and 4).
The longest diameter of pancreatic lesion varies from
1 cm up to 9 cm and SUVmax in pancreatic cancer ranged
from 4.5 up to 17.
PET/CT was statistically highly significant (P value
0.025) in assessment of pancreatic cancer, and Table 3
summarizes statistical analysis.
4. Discussion
Integrated positron-emission tomography and com-
puted tomography (PET/CT) is one of the most important
imaging techniques that had emerged in oncological prac-
tice in the last decade.
This study showed that PET/CT has higher sensitivity,
specificity, PPV, NPV, and accuracy compared to CT in diag-
nosis and monitoring of treatment response of pancreatic
cancer whereas CT could not differentiate post therapy
related changes from residual viable tumor. These are
matched with the results of previous studies conducted
by Bang et al. [9], Jung et al. [10], Delbeke and Martin
[11], Bampo et al. [12] and Asagi et al. [4].
Our study showed that 18 FDG-PET was also superior to
CT in the detection of distant metastasis as a result of
detection of bone marrow based osseous metastasis not
detected by CT. Distant metastasis was excluded in 12
cases out of examined 20 cases and also 18 FDG-PET can
Table 1
Patients’ demographics, risk factors, and clinicopathological characteristics.
Case Age Gender Weight Height ECGO
status
Risk factors Histopathology Site of
primary
tumor
Distant metastasis Lymph nod
metastasis
Baseline treatment Disease status
1 67 Male 54 155 Grade 2 Smoking Adenocarcinoma Head No distant
metastasis
No LN
metastasis
Surgery and chemo-
radiotherapy
Residual/Recurrent
2 47 Female 52 160 Grade 2 History of chronic
pancreatitis
Adenocarcinoma Neck No distant
metastasis
LN metasta s Not started
treatment yet
New case
3 61 Male 63 165 Grade 3 Diabetes and
smoking
Adenocarcinoma Head Liver, lung and
bone metastasis
LN metasta s Chemotherapy only Residual/Recurrent
4 58 Male 68 178 Grade 0 Smoking Neuroendocrine
carcinoma
Neck No distant
metastasis
No LN
metastasis
Surgery and
radiotherapy
Residual/Recurrent
5 73 Male 96 180 Grade 1 Smoking and
Obesity
Adenocarcinoma Tail Liver LN metasta s Chemotherapy only Residual/Recurrent
6 50 Male 74 165 Grade 1 Non Adenocarcinoma Head No distant
metastasis
No LN
metastasis
Chemotherapy only Residual/Recurrent
7 69 Male 88 168 Grade 1 Diabetes and
smoking
Adenocarcinoma Body and tail Liver No LN
metastasis
Not started
treatment yet
New case
8 56 Male 68 178 Grade 0 Smoking Neuroendocrine
carcinoma
Neck No distant
metastasis
No LN
metastasis
Surgery and radiotherapy Residual/Recurrent
9 68 Male 86 169 Grade 1 Diabetes and
smoking
Adenocarcinoma Body and tail Liver No LN
metastasis
Not started
treatment yet
New case
10 55 Female 57 159 Grade 1 Diabetes Intraductal papillary
mucinous neoplasm
Head No distant
metastasis
No LN
metastasis
Chemotherapy only Residual/Recurrent
11 47 Female 52 160 Grade 2 Diabetes Adenocarcinoma Neck No distant
metastasis
LN metasta s Chemotherapy only Residual/Recurrent
12 57 Male 72 162 Grade 1 Diabetes and
smoking
Adenocarcinoma Body Lung LN metasta s Chemotherapy only Residual/Recurrent
13 58 Male 70 180 Grade 0 Smoking Neuroendocrine
carcinoma
Neck No distant
metastasis
No LN
metastasis
Surgery and
radiotherapy
Residual/Recurrent
14 74 Male 96 180 Grade 2 Smoking and
Obesity
Adenocarcinoma Tail Liver LN metasta s Chemotherapy only Residual/Recurrent
15 63 Male 55 164 Grade 0 Smoking Dysplastic pancreatic
ductal cell
Body No distant
metastasis
LN metasta s Nano knife and
chemotherapy
Residual/Recurrent
16 64 Male 63 165 Grade 3 Diabetes and
smoking
Adenocarcinoma Head Liver, lung and
bone metastasis
LN metasta s Chemotherapy only Residual/Recurrent
17 50 Male 74 165 Grade 1 Smoking Adenocarcinoma Head No distant
metastasis
No LN
metastasis
Chemotherapy only Residual/Recurrent
18 67 Male 56 157 Grade 1 Smoking Adenocarcinoma Head No distant
metastasis
No LN
metastasis
Surgery and chemo-
radiotherapy
Residual/Recurrent
19 64 Male 50 160 Grade 1 Smoking Dysplastic pancreatic
ductal cell
Body No distant
metastasis
LN metasta s Nano knife and
chemotherapy
Residual/Recurrent
20 57 Male 72 162 Grade 1 Diabetes and
smoking
Adenocarcinoma Body Lung LN metasta s Chemotherapy only Residual/Recurrent
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Table 2
Description of the RBS and dose of FDG used for the patients.
RBS Dose of FDG
Mean 114.00 6.1450
Median 114.50 6.1000
Mode 74a 4.90a
Std. Deviation 20.630 .95448
Minimum 74 4.90
Maximum 150 8.20
RBS: random blood sugar, FDG: Fluoro-deoxy-glucose.
a Multiple modes exist. The smallest value is shown.
Table 3
Statistical analysis of results.
Assessment of treatment
response
Response
detected
by CT alone
Response
detected
by PET/CT
Sensitivity 77.8% 100%
Specificity 54.5% 88.9%
Positive predictive value 58.3% 91.7%
Negative predictive value 75% 100%
Accuracy 65% 95
P value 0.106 0.025
1282 E.A.I.N. Shaban / The Egyptian Journal of Radiology and Nuclear Medicine 47 (2016) 1275–1282detect primary pancreatic cancer in patients presented
with metastasis of unknown primary. These are matched
with the results of previous studies conducted by Bang
et al. [9], Burge et al. [13] and Ruf et al. [14].
The results of this study are discordant with those of
studies conducted by Parikh et al. [15], who showed that
18-F-FDG PET/CT has not been shown to offer additional
benefit in the initial diagnosis of pancreatic cancer and
by Conroy et al. [2], who showed that the sensitivity of
PET-CT is not higher than CT alone for the search of metas-
tasis which occurs mainly in the liver and the peritoneum.
Limitations of this study are small sample size, short
term follow-up, lack of survival analysis and lack of base-
line PET/CT.
5. Conclusion
Integrated PET/CT is a very useful tool in diagnosing
pancreatic cancer, and evaluating tumor response to ther-
apy and reliably detected local recurrences whereas CT is
sensitive for detection of hepatic metastases; FDG-PET
proved to be advantageous for the detection of non
locoregional and extra abdominal recurrences.
Conflict of interest
The authors declare that there are no conflict of
interests.Acknowledgment
I would like to thank Diagnostic Radiology and Medical
Imaging Department at Tanta University for their endless
support and everlasting cooperation.
References
[1] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M,
et al. Cancer incidence and mortality worldwide: sources, methods
and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:
E359–86.
[2] Conroy T, Bachet JB, Ayav A, Huguet F, Lambert A, Caramella C, et al.
Current standards and new innovative approaches for treatment of
pancreatic cancer. Eur J Cancer 2016;57:10–22.
[3] Madhavan B, Yue S, Galli U, Rana S, Gross W, Muller M, et al.
Combined evaluation of a panel of protein and miRNA serum-
exosome biomarkers for pancreatic cancer diagnosis increases
sensitivity and specificity. Int J Cancer 2015;136:2616–27.
[4] Asagi A, Ohta K, Nasu J, Tanada M, Nadano S, Nishimura R, et al.
Utility of contrast-enhanced FDG-PET/CT in the clinical management
of pancreatic cancer: impact on diagnosis, staging, evaluation of
treatment response, and detection of recurrence. Pancreas
2013;42:11–9.
[5] Bronstein YL, Loyer EM, Kaur H, Choi H, David C, Dubrow RA, et al.
Detection of small pancreatic tumors with multiphasic helical CT.
AJR Am J Roentgenol 2004;182:619–23.
[6] Vargas R, Nino-Murcia M, Trueblood W, Jeffrey Jr RB. MDCT in
Pancreatic adenocarcinoma: prediction of vascular invasion and
resectability using a multiphasic technique with curved planar
reformations. AJR Am J Roentgenol 2004;182:419–25.
[7] Chan SC, Ng SH, Chang JT, Lin CY, Chen YC, Chang YC, et al.
Advantages and pitfalls of 18F-fluoro-2-deoxy-D-glucose positron
emission tomography in detecting locally residual or recurrent
nasopharyngeal carcinoma: comparison with magnetic resonance
imaging. Eur J Nucl Med Mol Imag 2006;33:1032–40.
[8] Sahani DV, Bonaffini PA, Catalano OA, Guimaraes AR, Blake MA.
State-of-the-art PET/CT of the pancreas: current role and emerging
indications. Radiographics 2012;32:1133–58. discussion 58–60.
[9] Bang S, Chung HW, Park SW, Chung JB, Yun M, Lee JD, et al. The
clinical usefulness of 18-fluorodeoxyglucose positron emission
tomography in the differential diagnosis, staging, and response
evaluation after concurrent chemoradiotherapy for pancreatic
cancer. J Clin Gastroenterol 2006;40:923–9.
[10] Jung W, Jang JY, Kang MJ, Chang YR, Shin YC, Chang J, et al. The
clinical usefulness of 18F-fluorodeoxyglucose positron emission
tomography-computed tomography (PET-CT) in follow-up of
curatively resected pancreatic cancer patients. HPB (Oxford)
2016;18:57–64.
[11] Delbeke D, Martin WH. PET and PET/CT for pancreatic malignancies.
Surg Oncol Clin N Am 2010;19:235–54.
[12] Bampo C, Alessi A, Fantini S, Bertarelli G, De Braud F, Bombardieri E,
et al. Is the standardized uptake value of FDG-PET/CT predictive of
pathological complete response in locally advanced rectal cancer
treated with capecitabine-based neoadjuvant chemoradiation?
Oncology 2013;84:191–9.
[13] Burge ME, O’rourke N, Cavallucci D, Bryant R, Francesconi A, Houston
K, et al. A prospective study of the impact of fluorodeoxyglucose
positron emission tomography with concurrent non-contrast CT
scanning on the management of operable pancreatic and peri-
ampullary cancers. HPB (Oxford) 2015;17:624–31.
[14] Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski
C, et al. Detection of recurrent pancreatic cancer: comparison of
FDG-PET with CT/MRI. Pancreatology 2005;5:266–72.
[15] Parikh U, Marcus C, Sarangi R, Taghipour M, Subramaniam RM. FDG
PET/CT in pancreatic and hepatobiliary carcinomas: value to patient
management and patient outcomes. PET Clin 2015;10:327–43.
